EP Patent

EP3172209B1 — Tablet formulation of 2-fluoro-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide

Assigned to Novartis AG · Expires 2020-12-02 · 5y expired

What this patent protects

Patent listed against capmatinib-hydrochloride.

Drugs covered by this patent

capmatinib-hydrochloride (CAPMATINIB HYDROCHLORIDE)

Patent Metadata

Patent number: EP3172209B1
Jurisdiction: EP
Classification: —
Expires: 2020-12-02
Drug substance claim: No
Drug product claim: No
Assignee: Novartis AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.